← Leaderboards
Liewei Wang
Mayo Clinic Rochester
$11,536,599
Attributed
$14,772,662
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,317,900 · 11
By mechanism
U19$12,545,238 · 1
R01$8,243,003 · 7
T32$4,604,093 · 1
P50$1,433,714 · 1
K22$491,852 · 1
Top collaborators
- Richard M Weinshilboum13 shared
- Zhenkun Lou6 shared
- Roberto A Leon-Ferre1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Zhenkun Lou$18,569,951
- Scott H Kaufmann$29,002,745
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponsePathway InteractionsAffectGenesTumorRegulationVariantSignal TransductionPharmaceutical PreparationsMalignant Breast NeoplasmSamplingGrantBaseOverexpressionPhenotypeProteinsGene ExpressionPharmacogenomicsCellsAnimal ModelTrainingIn VitroMetabolismGenotype
Grant awards (48)
Ovcoming PARP Inhibitor Resistance$633,705
R01 · FY2025 · CA
Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC$472,447
R01 · FY2025 · CA · contact PI
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis$413,975
R01 · FY2025 · CA · contact PI
Training Grant in Clinical Pharmacology$347,010
T32 · FY2025 · GM · contact PI
Training Grant in Clinical Pharmacology$350,360
T32 · FY2024 · GM · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$345,528
R01 · FY2024 · CA · contact PI
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis$31,600
R01 · FY2024 · CA · contact PI
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis$481,745
R01 · FY2023 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$356,438
R01 · FY2023 · CA · contact PI
Training Grant in Clinical Pharmacology$326,578
T32 · FY2023 · GM · contact PI
Training Grant in Clinical Pharmacology$438,650
T32 · FY2022 · GM · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$356,438
R01 · FY2022 · CA · contact PI
Training Grant in Clinical Pharmacology$481,814
T32 · FY2021 · GM · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$363,713
R01 · FY2021 · CA · contact PI
Pharmacogenomic regulation of CYP transcription by TSPYL genes$309,449
R01 · FY2021 · GM · contact PI
Training Grant in Clinical Pharmacology$473,908
T32 · FY2020 · GM · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$363,713
R01 · FY2020 · CA · contact PI
Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy$363,713
R01 · FY2020 · CA · contact PI
Pharmacogenomic regulation of CYP transcription by TSPYL genes$309,982
R01 · FY2020 · GM · contact PI
Project 4: Pharmacogenomics of Aromatase Inhibitors in Early Stage Postmenopausal Breast Cancer$285,723
P50 · FY2020 · CA · contact PI
Training Grant in Clinical Pharmacology$420,332
T32 · FY2019 · GM · contact PI
Pharmacogenomic regulation of CYP transcription by TSPYL genes$302,100
R01 · FY2019 · GM · contact PI
Project 4: Pharmacogenomics of Aromatase Inhibitors in Early Stage Postmenopausal Breast Cancer$277,040
P50 · FY2019 · CA · contact PI
Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy$224,018
R01 · FY2019 · CA · contact PI
Training Grant in Clinical Pharmacology$403,665
T32 · FY2018 · GM · contact PI
Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy$363,713
R01 · FY2018 · CA · contact PI
Pharmacogenomic regulation of CYP transcription by TSPYL genes$302,100
R01 · FY2018 · GM · contact PI
Project 4: Pharmacogenomics of Aromatase Inhibitors in Early Stage Postmenopausal Breast Cancer$292,444
P50 · FY2018 · CA · contact PI
Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy$363,713
R01 · FY2017 · CA · contact PI
Project 4: Pharmacogenomics of Aromatase Inhibitors in Early Stage Postmenopausal Breast Cancer$298,042
P50 · FY2017 · CA · contact PI
Training Grant in Clinical Pharmacology$263,025
T32 · FY2017 · GM
Training Grant in Clinical Pharmacology$397,133
T32 · FY2016 · GM
Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy$363,713
R01 · FY2016 · CA · contact PI
Project 4: Pharmacogenomics of Aromatase Inhibitors in Early Stage Postmenopausal Breast Cancer$280,465
P50 · FY2016 · CA · contact PI
Training Grant in Clinical Pharmacology$384,070
T32 · FY2015 · GM
Pharmacogenetics of Phase II Drug Metabolizing Enzymes$3,141,483
U19 · FY2014 · GM
Training Grant in Clinical Pharmacology$317,548
T32 · FY2014 · GM
Pharmacogenetics of Phase II Drug Metabolizing Enzymes$3,058,214
U19 · FY2013 · GM
Pharmacogenomics and Mechanisms of Cytidine Analogues$285,880
R01 · FY2013 · CA · contact PI
Pharmacogenetics of Phase II Drug Metabolizing Enzymes$3,120,485
U19 · FY2012 · GM
Pharmacogenomics and Mechanisms of Cytidine Analogues$304,127
R01 · FY2012 · CA · contact PI
Pharmacogenetics of Phase II Drug Metabolizing Enzymes$3,225,056
U19 · FY2011 · GM
Pharmacogenomics and Mechanisms of Cytidine Analogues$304,127
R01 · FY2011 · CA · contact PI
Pharmacogenomics and Mechanisms of Cytidine Analogues$313,533
R01 · FY2010 · CA · contact PI
Pharmacogenomics of a Cytidine Analogue, Gemcitabine$164,486
K22 · FY2010 · CA · contact PI
Pharmacogenomics and Mechanisms of Cytidine Analogues$313,533
R01 · FY2009 · CA · contact PI
Pharmacogenomics of a Cytidine Analogue, Gemcitabine$164,484
K22 · FY2009 · CA · contact PI
Pharmacogenomics of a Cytidine Analogue, Gemcitabine$162,882
K22 · FY2008 · CA · contact PI